4SC Enters Next Phase of Drug Discovery Collaboration with SKK
News Jan 17, 2006
4SC AG and Sanwa Kagaku Kenkyusho Co., Ltd. have announced that they have achieved the first milestone and entered the next phase of their drug discovery collaboration which was started in January 2005.
To date 4SC has applied its proprietary virtual High Throughput Screening technology, 4SCan® to identify active agents against specific targets provided by SKK, followed by corresponding biological screening experiments.
A dedicated team of 4SC scientists shall now further optimize hits and leads with respect to certain properties like potency, selectivity and their in vitro ADMET profile.
The achievement of the first milestone triggers an undisclosed payment from SKK as well as the continuation of the partnership.
"We are extremely pleased with the quality and speed of the results achieved by 4SC," commented Mr. Satoshi Terao, SKK's Vice President for Research and Development.
"In the last months we have built an excellent relationship and we are looking forward to a continued fruitful collaboration."
"We are very proud that we have reached our first project milestone with SKK," stated Dr Daniel Vitt, CSO of 4SC.
"This success is yet another validation of the efficiency of our drug discovery platform and demonstrates the added value we can offer our partners within the biopharmaceutical industry worldwide."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018